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Akt is frequently activated in human cancers. How-
ever, it is unknown whether systemic inhibition of a
single Akt isoform could regress cancer progression
in cancers that are not driven by Akt activation.
We systemically deleted Akt1 after tumor onset in
p53/ mice, which develop tumors independently
of Akt activation. Systemic Akt1 deletion regresses
thymic lymphoma in p53/ mice emulating p53
restoration. Furthermore, pharmacological inhibition
of Akt selectively kills thymic lymphoma cells and not
primary thymocytes. Mechanistically, Akt1 inhibition
in p53/ thymic lymphoma inhibits Skp2 expression
and induces FasL, which is the primary cause of cell
death. Skp2 exerts resistance to cell death by antag-
onizing the induction of FasL and reducing FAS
expression, which is linked to cyclin D1 expression.
The results established a paradigm whereby sys-
temic Akt1 inhibition is sufficient to regress tumors
that are not driven by Akt activation and a mecha-
nism of cell survival by Skp2.
INTRODUCTION
The serine/threonine kinase Akt is perhaps the most frequently
activated oncoprotein in human cancers (reviewed in Bhaskar
and Hay, 2007). The pathways leading to its activation as well
as Akt itself are being targeted for cancer therapy. However,
there are three Akt isoforms (Akt1–3) encoded by three sepa-
rate genes. These isoforms are about 85% identical to each
other, and it is impossible to distinguish among them with
respect to substrate specificity in in vitro kinase assay (Walker
et al., 1998). Nevertheless, it is possible that the different iso-
forms are functionally different in vivo. However, it is unknown
which isoform should be preferentially targeted and for which
type of cancer, without eliciting adverse physiological conse-
quences. It is also not known whether Akt could be targeted
for therapy of cancers that are not driven directly or indirectly
by Akt activation.610 Cell Reports 12, 610–621, July 28, 2015 ª2015 The AuthorsPreviously, we and others showed that germline deletion of
Akt1 exerts resistance to Pten-deletion-induced tumorigenesis
(Chen et al., 2006), skin carcinogenesis (Skeen et al., 2006),
mammary and salivary gland tumorigenesis (Ju et al., 2007; Mar-
oulakou et al., 2007; Skeen et al., 2006), and lung carcinogenesis
(Hollander et al., 2011). The germline deletion of Akt1 in the
mouse does not have adverse physiological consequences,
and Akt1/ mice live significantly longer than control WT mice
(Chen et al., 2006). By contrast, germline deletion of Akt2 in-
duces insulin resistance and does not inhibit tumor development
in mouse models of breast cancer and in Pten+/mice (Maroula-
kou et al., 2007; Xu et al., 2012). However, studies using germline
deletions of Akt isoforms cannot determine whether Akt is
required for tumor progression and do not emulate drug therapy.
To address whether systemic Akt1 deletion after tumor onset
could inhibit tumor progression even in tumors, which are not
driven by Akt activation, we examined the ability of systemic
Akt1 deletion to inhibit tumor progression in p53/ mice. We
found that the systemic deletion of Akt1 was sufficient to regress
or halt the progression of thymic lymphoma in p53/ mice
similar to what observed after p53 restoration in thesemice (Ven-
tura et al., 2007). The deletion of Akt1 in p53/ thymic lym-
phoma is sufficient to inhibit cell-cycle progression and induces
apoptosis, which could be recapitulated by a pharmacological
inhibitor of Akt. The cytotoxic effect of Akt inhibition on p53/
thymic lymphoma is selective as it is not cytotoxic to normal
thymocytes. However, hyperactivation of Akt in p53/ thymic
lymphoma exerts resistance to pharmacological inhibitor of
Akt. The induction of FasL expression by the inhibition of Akt
and activation of FOXO appears to be the predominant cause
of cell death. Interestingly ectopic expression of Skp2 in the
p53/ thymic lymphoma cells also exerts resistance to Akt inhi-
bition. Skp2 exerts resistance to cell death at least in part by the
inhibition of FasL and Fas expression. It was recently reported
that D cyclins promote survival of hematopoietic cells through in-
hibition of Fas and FasL expression in a E2F1-dependent
manner (Choi et al., 2014). Consistently, we found that the
ectopic expression of Skp2 also elevates Cyclin D1 expression
and reduces p27 expression, which are known to activate
E2F1, and thus could explain the mechanism by which Skp2
inhibits Fas and FasL expression. Taken together, these results
established a paradigm whereby Akt1 inhibition is therapeutic
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Figure 1. Systemic Deletion of Akt1 in
p53/ Mice after Tumor Onset Increased
Lifespan
(A) Schematic illustration showing crossing of
mice to generate p53/Akt1f/f/R26CreERT2 mice.
(B) Immunoblot showing Akt1 deletion in several
mouse tissues after injection of tamoxifen (Tam) to
6-week-old p53/Akt1f/f/R26CreERT2 mice.
(C) Kaplan-Meier plot showing lifespan of p53/
or p53/Akt1f/f/R26CreERT2 mice after tamoxifen
injection at 6 weeks of age (n = 10).even for cancers that are not driven by Akt activation. These re-
sults suggest that Akt inhibitors could be used effectively to treat
cancers that are driven by the loss of p53 such as in Li-Fraumeni
syndrome (LFS) patients. Although only about 20% of LFS pa-
tients have a compete loss of p53, most of the p53 mutations
in LFS are occurring in the DNA binding domain and act in a
dominant manner to inhibit WT p53 (Malkin, 2011). The results
also suggest that high Skp2 expression could predict resistance
to Akt inhibition and that the inhibition of both Akt and Skp2
might be considered for a long-term therapeutic effect.
RESULTS
Systemic Deletion of Akt1 in p53/ Mice Increases
Lifespan and Halts the Progression of Thymic
Lymphoma in These Mice
To determine the ability of systemic Akt1 ablation to regress or
attenuate tumor progression, we have generated Akt1f/f mice
(Figures S1A and S1B) and crossed these mice with R26CreERT2
mice, in which CreERT2 was inserted in the ubiquitously
expressed ROSA26 locus (Ventura et al., 2007), to generate
Akt1f/f/R26CreERT2 mice (Figures 1A and S1C). CreERT2 is an
inducible Cre recombinase fused in frame to a mutated ligand-
binding domain of estrogen receptor, which responds only to
hydroxytamoxifen (4-OHT) and not to estrogen. To determine
whether systemic Akt1 inhibition could regress or inhibit progres-
sion of tumors that are not driven by lesions that activate Akt, we
crossed Akt1f/f/R26CreERT2 mice with p53/ mice to generate
p53/Akt1f/f/R26CreERT2 mice (Figure 1A). Injection of tamox-
ifen to the mice 6 weeks after birth successfully deletes Akt1 in
all tissues tested (Figures 1B and S1C). The p53/mice develop
thymic lymphomawith anearly onset andeventually develop also
sarcoma (Ventura et al., 2007). The mice die of these tumors
within 6 months after birth, and restoration of p53 regresses
the lymphoma with increased apoptosis and inhibits the growthCell Reports 12, 610–6of sarcoma, indicating that these tumors
are highly dependent on p53 deletion
(Ventura et al., 2007). We have generated
cohorts of p53/Akt1f/f/R26CreERT2 and
p53/R26CreERT2 mice. The mice were
injected with tamoxifen for 7 consecutive
days, 6 weeks after birth when they start
developing thymic lymphoma. As shown
in Figure 1C, the systemic deletion of
Akt1 substantially increased the medianlifespan of p53/ mice from 16 weeks to 29 weeks. We did
not see a significant change in the lifespan of control
p53/R26CreERT2 mice (data not shown).
To further substantiate our findings and demonstrate that sys-
temic Akt1 ablation is sufficient to regress or halt thymic lym-
phoma progression in p53/ mice, we monitored in vivo tumor
progression by MRI prior to and after treatment with tamoxifen.
Cohorts of p53/Akt1f/f/R26CreERT2 and p53/R26CreERT2
mice were monitored to detect in vivo lymphoma as previously
described (Ventura et al., 2007). When tumors detected by MRI
reached the volume of approximately 200 mm3, mice were
treated with tamoxifen, and tumor growth was followed as previ-
ously described (Ventura et al., 2007). As shown in Figures 2A
and 2B, tumor size was significantly reduced 12–16 days after
the administration of tamoxifen into p53/Akt1f/f/R26CreERT2
mice, while at the same time in untreated mice tumors grew
approximately by about 5-fold (Figure 2A). Injection of tamoxifen
into control p53/R26CreERT2 mice did not reduce tumor
growth (Figure 2B). In general, the deletion of Akt1 by tamoxifen
treatment either halts or regresses tumor growth while at the
same time in control mice tumor grew by 2- to 6-fold (Figure 2C).
Moreover, analysis of sections from the tumor mass that was left
after Akt1 deletion revealed a massive apoptosis as indicated by
cleaved caspase-3 staining and a relatively few Ki67 positive
cells (Figure 2D). These results indicate that systemic deletion
of Akt1 after tumor onset in p53/ mice, which emulate drug
therapy, is sufficient to regress p53/ thymic lymphoma. More-
over, the effect of Akt1 deletion on thymic lymphoma in p53/
mice is similar to what observed after restoration of p53 in these
mice (Ventura et al., 2007).
The Deletion of Akt1 in p53/ Thymic Lymphoma Cells
Induces Cell Death and Inhibits Cell Proliferation
To further establish the role of Akt1 in p53/ thymic lymphoma,




Figure 2. Systemic Akt1 Deletion in p53/ Mice Halts or Regresses Tumor Growth In Vivo
(A and B) MRI images (left) and calculated tumor volume (right) in response to tamoxifen of p53/Akt1f/f/R26CreERT2 (A and B) or p53/R26CreERT2 mice (B).
***p < 0.001 Tam versus vehicle; zzzp < 0.0001, zz p < 0.005, z p < 0.01 versus day 0.
(C) Summary of individual tumor responses to systemic Akt1 deletion 16 days after tamoxifen treatment or vehicle alone of p53/Akt1f/f/R26CreERT2 mice.
(D) Representative tumor sections from two tumors after regression as determined by MRI showing cleaved caspase-3 (CC3) and Ki67 staining. Data are
presented as an average of three measurements ±SEM.p53/R26CreERT2 and p53/Akt1f/f/R26CreERT2 mice and
were exposed to 4-OHT in vitro (Figure 3A). The deletion of
Akt1 in these lymphoma cell lines profoundly inhibited the growth612 Cell Reports 12, 610–621, July 28, 2015 ª2015 The Authorsof the cells (Figure 3B). This effect is due to both induction
of apoptosis and inhibition of proliferation as measured by bro-
modeoxyuridine (BrdU) incorporation (Figure 3C). Thus, Akt1
Figure 3. Ex Vivo Deletion of Akt1 in Thymic
Lymphoma Cells Derived from p53/
Akt1f/f/R26CreERT2 Mice Inhibits Prolifera-
tion and Induces Cell Death
(A) Strategy of isolating thymic lymphoma cell lines
(top) and immunoblot showing Akt1 deletion after
exposure to 4-OHT (bottom).
(B) Proliferation of two independent isolated cell
lines in response to 4-OHT. Cells were exposed to
4-OHT for 3 days, and cell number was deter-
mined in the indicated time points. Data are
presented as an average of three independent
experiments in triplicates ±SEM. ***p < 0.001,
**p < 0.01, *p < 0.05 versus 4-OHT 300 nM
and 1 mM.
(C) BrdU (bromodeoxyuridine) incorporation as
measured by anti-BrdU staining and cell death as
measured by PI (propidium iodide) staining using
flow cytometry. Cells were exposed to 4-OHT for
3 days and were subjected to BrdU incorporation
and PI staining at the indicated time points. Data
are presented as an average of three independent
experiments in triplicates ±SEM. *p < 0.05; ns, not
significant.deletion is sufficient to induce both cell death and cell-cycle
arrest in p53/ thymic lymphoma. In general, Akt1 deletion by
itself has only cytostatic effect and can only render cells more
susceptible to cell death by the presence of other apoptotic stim-
uli (Chen et al., 2001). Notably, the p53/ thymocytes do not
display activation of Akt when compared to control thymocytes,
and Akt activity did not significantly change after re-expressing
p53 in the p53/ thymic lymphoma cells (Figure S2). Thus,
clearly Akt is not hyperactivated in thymic lymphoma driven by
p53 deletion. Ectopic expression of a myristoylated Akt1
(mAkt), a constitutively active form of Akt, exerts resistance
to the deletion of Akt1 by 4-OHT (Figures S2C and S2D).
Finally, we injected either p53//R26CreERT2 or p53/Akt1f/f/
R26CreERT2 lymphoma cells into nude mice and followed tumor
growth (Figure 4A). When tumor size reached 60 mm3 in volume,
the mice were treated with tamoxifen. While tumor growth of
p53//R26CreERT2 lymphoma cells was not affected by tamox-Cell Reports 12, 610–ifen treatment, tumor growth of p53/
Akt1f/f/R26CreERT2 lymphoma cells in
the treated mice was halted when
compared to tumor growth of untreated
mice (Figures 4B and 4C). When, tumor
section samples were analyzed for cell
proliferation or cell death as measured
by BrdU incorporation and cleaved cas-
pase-3, respectively, a profound reduc-
tion in proliferation and increased
apoptosis were observed (Figure 4D).
Thus, the in vivo results recapitulate the
results obtained ex vivo.
We then wanted to find out whether
pharmacological inhibition of Akt1 could
recapitulate Akt1 deletion. Since there
are no specific inhibitors of Akt1, we em-ployed MK2206, which is an allosteric inhibitor of Akt that
is commonly used in clinical trials. MK2206 inhibits Akt1, Akt2,
and Akt3 with IC50 of 8, 12, and 65 nM, respectively (Hirai
et al., 2010). We first exposed the thymic lymphoma cells to
MK2206 and compared its effect to the effect induced by Akt1
deletion. We found a similar effect of MK2206 on the proliferation
of the cells (Figure 5A) as well on BrdU incorporation (Figure 5B)
and apoptosis (Figure 5C) to that observed after the induction of
Akt1 deletion. Likewise in vivo tumor growth of these cells was
halted after treatment with MK2206 (Figure 5D) similar to what
was observed after systemic deletion of Akt1. Thus, the pan-
Akt inhibitor could recapitulate the conditional deletion of Akt1
to inhibit the progression of cancer that is not driven by onco-
genic signaling that activates Akt. Importantly, the effect of
MK2206 on p53/ thymic lymphoma is selective because we
found that the cytotoxic effect on primary normal thymocytes
is minimal in comparison to the lymphoma cells (Figure 5E).621, July 28, 2015 ª2015 The Authors 613
Figure 4. The Deletion of Akt1 Inhibits the
Growth of Xenographic p53/ Thymic Lym-
phoma Tumors by Inhibiting Proliferation
and Inducing Apoptosis
(A) Flowchart depicting the strategy to determine
tumor response in xenograft assays. Cells isolated
from the thymic lymphoma were cultured and
inoculated into nude mice. When tumor size
reached 60 mm3, mice were treated with tamox-
ifen, and tumor growth was determined.
(B) Tumor growth curves of p53/R26CreERT2 or
p53/Akt1f/f/R26CreERT2 cells in response to
tamoxifen. Data are presented as an average of
ten tumors in five mice per each cell line and
per each treatment ±SEM (n = 9). **p < 0.001
versus Tam.
(C) Representative tumors from vehicle- or
tamoxifen-treated mice (left) and immunoblot
showing the extent by which Akt1 deletion
affected total serine 473 phosphorylation of Akt in
various tumors (right).
(D) Representative tumor sections from vehicle-
or tamoxifen-treated mice showing cleaved
caspase-3(CC3) and BrdU incorporation (left
panels). Quantification of CC3 or BrdU positive
cells in randomly selected six fields from three
different tumors (right panels). Data are presented
as an average ±SEM. **p < 0.001.Taken together, these results showed that Akt activity is also
required for tumors that are not driven by signaling pathways
that activate Akt, and that Akt ablation is therapeutic for thymic
lymphoma induced by p53 deletion.
Interestingly, we previously showed that germline deletion of
Akt1 sensitized primary thymocytes to killing by gamma-irradia-
tion (Chen et al., 2001). Thus, it is possible that the deletion of
p53, which increases DNA damage, similarly sensitizes thymo-
cytes to killing by Akt inhibition. Consistently, we found that hu-
man cancer cells lacking p53 are profoundly more sensitive to
cell death after inhibition of Akt then cancer cells proficient for
p53. We employed three well-established pairs of colorectal
cancer cell lines in which p53 is either WT or was somatically
deleted (Sur et al., 2009; Figure S3). As shown in Figure 5F, the
p53-deficient cells are highly sensitive to cell death after expo-
sure to MK2206 when compared to the p53-proficient cells.
These results suggest that the hypersensitivity to Akt inhibition614 Cell Reports 12, 610–621, July 28, 2015 ª2015 The Authorsexerted by p53 deficiency could be
extended to different types of cancer.
The Mechanisms by which the
Deletion of Akt1 Inhibits
Proliferation and Induces Cell
Death in p53/ Thymic Lymphoma
We previously showed that mTORC1 is
the most critical downstream effector of
Akt, required for cell proliferation and
tumorigenesis (Skeen et al., 2006). Our
results showed that, upon deletion of
Akt1 by 4-OHT, there was a decrease in
FOXO phosphorylation (Figure 6A) and amarked reduction in mTORC1 activity as measured by the phos-
phorylation of S6 and 4EBP1 (Figure 6B). As we previously
showed, mTORC1 activity and its downstream effector, the initi-
ation factor of mRNA translation, eIF4E, are required for the Skp2
mRNA translation, and therefore for its expression at the protein
level (Nogueira et al., 2012). Indeed, we found a significant
decrease in Skp2 expression following the reduced mTORC1
activity (Figure 6B). Skp2 is a F-box protein that mediates the
degradation of p27 and other cell-cycle inhibitory proteins (Na-
kayama et al., 2004; Pagano, 2004). Similarly, Akt inhibition by
MK2206 inhibited FOXO phosphorylation and mTORC1 activity
and elevated p27 expression (Figure 6C). Thus, the reduced
mTORC1 activity in combination with the induced FOXO activity
could explain the high level of p27 as well as the inhibition of pro-
liferation following Akt inhibition in p53/ thymic lymphoma. We
also found a decrease in the anti-apoptotic protein Mcl-1 after






Figure 5. MK2206 Treatment Recapitulates
the Response to Akt1 Deletion and Selec-
tively Kills Lymphoma Cells In Vitro
(A) Proliferation of p53/R26CreERT2 or p53/
Akt1f/f/R26CreERT2 lymphoma cells in response to
two doses of MK2206. Data are presented as an
average of three independent experiments ±SEM.
***p < 0.001, **p < 0.01 versus DMSO.
(B and C) BrdU incorporation (B) and cell death (C)
in response to MK2206. Data are presented as an
average of three independent experiments in trip-
licates ±SEM. ***p < 0.001, **p < 0.01, *p < 0.01
versus DMSO in each group.
(D) Xenographic tumor growth of p53/Akt1f/f/
R26CreERT2 lymphoma cells in response to
MK2206. When tumor size reached 60 mm3, mice
were treated with either capistol or MK2206. Data
are presented as an average of ten tumors in five
mice per capistol or MK2206 treatment ±SEM
(n = 9); ***p < 0.001.
(E) Assessment of apoptosis in response to 1 mM
MK2206 of normal thymocytes isolated from three
individual mice or of p53/ thymic lymphoma
cells. Data are presented as an average of three
independent experiments in triplicates ±SEM.
***p < 0.001 versus DMSO and thymic lymphoma
versus normal primary thymocytes.
(F) Fold change in apoptosis in response to
MK2206 in the colorectal HCT116, SW48, and
DLD-1 and their isogenic p53/ cell lines. Cells
were exposed to either the indicated concentra-
tions of MK2206 or DMSO, and apoptosis was
quantified 48 hr later. Data presented as an
average of two independent experiments in tripli-
cates ±SEM. ***p < 0.001 p53/ versus WT.dependency of Mcl-1 mRNA translation onmTORC1 activity and
eIF4E (Wendel et al., 2007), as well as the increase ofMCL-1 pro-
tein stability by Akt through the inhibition of GSK3 (Maurer et al.,
2006). In addition, the mRNAs for the FOXO targets pro-
apoptotic proteins Bim and FasL (Figures 6D and 7C), as well
as FasL protein, which its expression, as determined by fluores-
cence-activated cell sorting (FACS) analysis, overlaps with cells
undergoing cell death (Figures 6E and S4), were elevated after
Akt inhibition. Thus, the reduced Mcl-1 expression together
with the higher expression of Bim and FasL could explain the in-
duction of cell death after Akt inhibition. Surprisingly, however,
we found that ectopic expression of Skp2 in p53/ thymic lym-
phoma exerted resistance to cell death induced by Akt inhibition
almost to the same extent as by mAkt (Figure 7A). Analysis of
protein extracts derived from these cells before and after treat-
ment showed that Skp2 protein expression declined in control-Cell Reports 12, 610–treated but only modestly in mAkt-treated
cells, and the elevation of p27 was
observed in control-treated cells but not
in Skp2- or mAkt-treated cells (Figure 7B).
Unlike in mAkt-treated cells, mTORC1 ac-
tivity, as measured by S6K1 phosphoryla-
tion and 4EBP1 mobility shift, as well as
FOXO phosphorylation are still inhibited
to a similar extent in control and Skp2-ex-pressing cells. MCL-1 protein levels were reduced to a similar
extent in control and Skp2-expressing cells (Figure 7B). None-
theless, cleaved caspase-3 levels were profoundly reduced in
Skp2 expression cells, consistent with the resistance of these
cells to cell death induced by Akt inhibition. Thus, Skp2 could
partially recapitulate the resistance to cell death exerted by acti-
vated Akt in p53/ thymic lymphoma cells and overrides
mTORC1 inhibition and FOXO activation. Therefore, the resis-
tance to cell death induced by Skp2 overexpression seems to
be independent of mTORC1 activity, FOXO phosphorylation, or
Mcl-1 expression. These results were unexpected, but, although
we did not observe a significant change in the induction of Bim
mRNA in Skp2-expressing cells, we found that Fas ligand
(FasL) expression was significantly reduced (Figure 7C). This
could explain in part the resistance of p53/ thymic lymphoma
cells overexpressing Skp2 to Akt inhibition. To verify the role of621, July 28, 2015 ª2015 The Authors 615
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B Figure 6. Activation of FOXO and Inhibition
of mTORC1 and Skp2 Expression in
Response to Akt1 Deletion or Akt Inhibition
by MK2206
(A) FOXO phosphorylation at day 4 (D4) or day 5
(D5) after deletion of Akt1 by 4OHT in p53/
Akt1f/f/R26CreERT2 lymphoma cells.
(B) Phosphorylation of 4EBP1, S6, and the
expression of Skp2 at day 4 or 5 after deletion of
Akt1 by 4OHT in p53/Akt1f/f/R26CreERT2 lym-
phoma cells.
(C) Immunoblot showing FOXO phosphorylation,
mTORC1 activity as measured by 4EBP1 mobility
shift and S6 phosphorylation, p27 and MCL-1
protein levels, and CC3 after treatment of
p5353unoblot showing FO lymphoma cells with
MK2206 at the indicated time points.
(D) Fas ligand (FasL) and Bim mRNA levels
as measured by qRT-PCR after treatment of
p53/Akt1f/f/R26CreERT2 lymphoma cells with
MK2206 for 18 hr. Data are presented as an
average of three independent RNA prepara-
tions ±SEM. **p < 0.001, *p < 0.05.
(E) FACS analysis of FasL expression in cells
treated with DMSO or 1 mM MK-2206 for 18 hr.
Data are presented as an average of three
independent experiments in triplicates ±SEM.
**p < 0.005.FasL in apoptosis, we monitored caspase-8 cleavage and found
that it is increased in the control-treated cells but is inhibited in
Skp2-overexpressing cells and mAkt-expressing cells (Fig-
ure 7D), to a similar extent as observed with caspase-3 cleavage
(Figure 7B). Furthermore, inhibition of caspase-8 activity or FAS
silencing inhibited cell death induced by Akt inhibition. We em-
ployed the caspase-8 inhibitor Z-LETD-FMK and showed that
it markedly inhibited cell death induced by Akt inhibition (Fig-
ure 7E), without affecting the induction of FASor FasL (Figure S5).
Silencing FAS using small interfering RNA (siRNA) (Figure S6A)616 Cell Reports 12, 610–621, July 28, 2015 ª2015 The Authorsinhibited the induction of FAS and in-
hibited apoptosis induced by Akt inhibi-
tion (Figure 7F). All together, these results
strongly indicate that the predominant
initiator of apoptosis, induced by Akt
inhibition in p53/ thymic lymphoma, is
FasL. Consistently, although we found
that Bim mRNA levels are highly induced
by the inhibition of Akt, we did not find a
significant change in the major expressed
isoform BIM-EL protein, and only small
changes in the alternatively spliced iso-
form BIM-L (Figure S6B). Only in cells
expressing activated Akt were the pro-
tein levels of the three BIM isoforms
decreased.
Given that it was recently shown that D
cyclins promote cell survival in hemato-
poietic cells by the inhibition of FasL and
Fas receptor (Fas) expression (Choi
et al., 2014), and since we did not find sig-nificant changes in BIM protein expression by Skp2 (Figure S6B),
we analyzed cyclin D1 level in Skp2-overexpressing cells and
found that it is significantly elevated (Figure 7G). The mechanism
bywhich D cyclins inhibit FasL and Fas expression appears to be
through the induction and activation of E2F1 (Choi et al., 2014).
Therefore, the inhibition of p27 and the induction of cyclin D1
by Skp2 raise the possibility that Skp2 inhibits FasL mRNA via
the phosphorylation of Rb and the activation of E2F. It is there-
fore expected that Skp2 overexpression would also reduce the
expression of Fas. Indeed, we found that Skp2 overexpression
also markedly reduced the expression of Fas after Akt inhibition
(Figure 7H). The results suggest amechanism by which Skp2 an-
tagonizes Akt-inhibition-mediated cell death in p53/ thymic
lymphoma (Figure 7I). Furthermore, the results uncovered a
mechanism by which Skp2 could promote cell survival.
We clearly showed that the predominant mechanism, which
selectively sensitizes p53/ thymic lymphoma to cell death by
Akt inhibition, is mediated by FAS and FASL. However, as we
indicated above, it is possible that p53 deficiency in general sen-
sitizes cells to cell death by Akt inhibition as was shown for the
isogenic colorectal cancer cells (Figure 5F). Akt inhibition could
induce cell death by multiple mechanisms, and the mechanism
that we have uncovered in the thymic lymphoma cells may not
apply to the colorectal cancer cell lines. We found that Akt inhi-
bition, despite inducing higher levels of apoptosis in the p53-
deficient human cancer cells, inhibits FOXO phosphorylation to
a similar extent in p53-proficient and p53-deficient human can-
cer cells (Figure S7A). Unlike what was observed in the p53/
thymic lymphoma cells, we did not find any significant and
consistent changes in MCL-1 protein level upon Akt inhibition
(Figure S7A). BIM and FAS protein levels were also did not
consistently change upon Akt inhibition, although in the p53/
HCC116 cells we found a modest elevation of FAS and BIM pro-
teins (Figure S7A). We also did not find consistent changes in
FasL expression. Only a modest increase of FasL mRNA was
found in p53/ SW40 and p53/ DLD-1 cells when compared
to the isogenic p53-proficient cells (Figure S7B). Nevertheless,
caspase-3 cleavage was markedly induced in the p53-deficient
cells when compared to the p53-proficient cells (Figure S7C).
These results support the notion that regardless of the mecha-
nism p53 deficiency sensitizes cells to cell death induced by
the inhibition of Akt.
DISCUSSION
It is known that germline deletion of Akt1 is sufficient to inhibit tu-
mor development in several mouse models of cancer, which are
associated with Akt activation. However, these results do not
address whether Akt1 inhibition is sufficient to inhibit or regress
tumors after tumor onset. In addition, it is not clear whether Akt
inhibitors could be therapeutic for cancers in which activation of
Akt is not implicated. Akt hyperactivation is perhaps one of the
most frequently occurring events in human cancers, and there-
fore these cancers are rationale candidates for Akt inhibition
therapy, but it is not known whether Akt inhibition is valuable in
cancers, which do not display activation of Akt. Finally, it is not
clear what are the potential mechanisms that could be devel-
oped by cancer cells to resist Akt inhibition therapy. In the cur-
rent studies, we addressed these three questions and showed
that systemic deletion of Akt1 in mice is therapeutic for p53/
thymic lymphoma that does not display Akt activation.
The effect of systemic Akt1 deletion on the lifespan extension
of p53/ tumor bearing mice is profound but is not sufficient to
reach normal lifespan. Although theMRI studies showed that the
systemic Akt1 deletion either halt the growth or regress the
p53/ thymic lymphoma, it is possible that other tumors devel-
oped in p53/ mice caused the eventual mortality. Usually
p53/ mice also develop high incidence of sarcoma, but wehave not detected sarcomas within the time frame that the
mice were treated possibly because of the C57Bl6 background
of the mice used in our studies. We did observe, however, sar-
comas in older mice, which could contribute to the mortality
even after Akt1 deletion. Alternatively or additionally, thymic lym-
phoma cells that escaped the deletion could contribute to the
mortality. Finally, the possibility that p53/ mice have a shorter
lifespan regardless of tumor development cannot be completely
excluded. Future studies are required to determine whether
other types of tumors, which are driven by p53 deletion or by
mutated p53, such as sarcoma, could be also targeted by Akt1
inhibition.
The germline deletion of Akt1 in themouse has onlyminor con-
sequences, and, in fact, Akt1/ mice live longer than wild-type
mice (Chen et al., 2006). The systemic deletion of Akt1 in adult
mice does not induce any overt phenotype, and therefore our re-
sults strongly suggest that Akt1 specific inhibition could be well
tolerated and it is an efficient cancer therapy strategy even if the
cancer cells do not display Akt activation. The results provide a
paradigm that might expand the spectrum of cancer types that
could be candidates for Akt inhibition therapy. Restoration of
p53 hadbeen suggested as a strategy for cancer therapy (Martins
et al., 2006; Ventura et al., 2007; Wang et al., 2011). However,
restoration of p53 is difficult to achieve, and thus our results sug-
gest a feasible strategy for therapy of cancers that are driven by
the lossofp53.Moreover, our results couldbeextended tohuman
cancer cells deficient for p53aswe found that p53deficiency sen-
sitizes human cancer cells to cell death induced by Akt inhibition.
As expected, we found a decrease in FOXO phosphorylation
and mTORC1 activity after Akt1 deletion or Akt inhibition in
p53/ thymic lymphoma. The activation of FOXO resulted an in-
crease in its pro-apoptotic transcriptional targets Bim and FasL.
The inhibition of Akt also reduced the protein levels of Mcl-1. Akt
inhibition could reduce the steady-state level of Mcl-1 through
inhibition of its mRNA translation, which is highly dependent on
eIF4E (Wendel et al., 2007) or through its destabilization by
GSK3, which is phosphorylated and inactivated by Akt (Maurer
et al., 2006). The combination of the elevated Bim and FasL
with the reducedMcl-1 level could explain the cell death induced
by Akt inhibition in p53/ thymic lymphoma. However, our re-
sults strongly indicated that the predominant cause of cell death
is FasL mediated. Skp2 expression was also reduced after Akt
inhibition. The reduced Skp2 expression is likely due to reduced
Skp2 mRNA translation since it is highly dependent on Akt and
on its downstream effectors mTORC1 and eIF4E, as we had
shown previously (Nogueira et al., 2012). However, we observed
that in the thymic lymphoma cells exogenous Skp2 protein is
also reduced upon Akt inhibition, which cannot be explained
only by mRNA translation. Other results showed that Skp2 is
directly phosphorylated by Akt, which in turn maintains its cyto-
plasmic localization and stability (Gao et al., 2009; Lin et al.,
2009), but these results were challenged by others (Bashir
et al., 2010). We expected that ectopic Skp2 expression would
override the inhibition of cell proliferation induced by Akt inhibi-
tion in p53/ thymic lymphoma. Surprisingly, we found that
high level of ectopic Skp2 expression in p53/ thymic lym-
phoma exerts resistance to cell death induced by Akt inhibition.








Figure 7. Ectopic Expression of Skp2 or mAkt in p53/ Thymic Lymphoma Cells Exerts Resistance to MK2206
(A) Induction of cell death of control GFP-expressing cells, Skp2, or mAkt-expressing cells after treatment with MK2206 for 18 hr. Data are presented as an
average of three independent experiments ±SEM.
(B) Immunoblot showing the phosphorylation of Skp2 expression, FOXO3 phosphorylation, p27 expression, mTORC1 activity as measured by S6 phosphory-
lation and 4EBP1 mobility shift, Mcl-1 and cleaved caspase-3 (CC3) expression in GFP-, Skp2-, or mAkt-expressing cells following treatment with MK2206
for 18 hr.
(legend continued on next page)
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variety of cancer cell lines elicits cell death (Jiang et al., 2005; Lee
and McCormick, 2005). In particular, pRb-deficient cancer cells
are sensitized to apoptosis induced by Skp2 silencing with no
effect on proliferation. These results suggest that Skp2 has a
role in cell survival, which is independent from its role in cell pro-
liferation (Wang et al., 2010a). Interestingly, high Skp2 expres-
sion was implicated in T cell lymphoma inmice and in high-grade
lymphomas in human (Latres et al., 2001). Expression of Skp2 in
T cells in mice profoundly increased the incidence of T cell lym-
phoma induced by oncogenic N-Ras (Latres et al., 2001), and
mice lacking CREB binding protein (CBP) develop T cell lympho-
magenesis with concomitant elevated Skp2 expression (Kang-
Decker et al., 2004).We found that Skp2 decreased the induction
of FasL and Fas by MK2206 treatment. Our results showed that
the predominant mechanism by which Akt inhibition promotes
cell death in p53/ thymic lymphoma is via FASL and FAS.
Both FAS silencing and caspase-8 inhibition inhibited the cell
death induced by Akt inhibition. Consistently, it was reported
that the deficiency of FasL accelerates development of tumors
in p53+/ mice (Embree-Ku and Boekelheide, 2002). Skp2 over-
expression negates apoptosis induced by Akt inhibition by pro-
hibiting the induction of FasL and by reducing the expression of
FAS. As was recently reported, D cyclins promote hematopoietic
cell survival through inhibition of FasL and Fas expression via
E2F1 (Choi et al., 2014). Since we found that Skp2 overexpres-
sion induced cyclin D1 expression and inhibits p27 expression,
which eventually could activate E2F1, we proposed a mecha-
nism by which Skp2 negates Fas-mediated apoptosis induced
by FOXO (Figure 7I). Thus, Skp2 exerts resistance to Akt inhibi-
tion and could override both inhibition ofmTORC1 and activation
of FOXO and could predict resistance to Akt inhibition therapy.
Consistently, it was reported that resistance to rapamycin is
linked to high Skp2 expression (Totary-Jain et al., 2012).
Although Skp2 had been previously implicated in inhibition of
apoptosis, the mechanism by which it exerts resistance to
apoptosis is unclear. Our results provided a mechanism by
which Skp2 could promote resistance to FAS-mediated cell
death. The hypersensitivity to Akt inhibition exerted by p53 defi-
ciency, although it was demonstrated only in one particular
mouse model of p53/ thymic lymphoma, could be potentially
generalized to other cell types in future work. However, the
mechanism by which Akt inhibition sensitizes p53/ human
epithelial cancer cells to cell death appears to be different from
the mechanism uncovered in the thymic lymphoma cells, and
could be dependent on the cells’ milieu.
In summary, the results presented in this study provided a
concept showing that systemic Akt1 inhibition alone is sufficient(C) Expression of FasL and Bim asmeasured by RT-PCR in GFP-, Skp2-, or mAkt-
as an average of three independent RNA preparations ±SEM. **p < 0.01, *p < 0.
(D) Immunoblot showing the level of cleaved caspase-8 in GFP-, Skp2-, or mAkt
(E) Induction of cell death of p53/ thymic lymphoma cells after treatment with
inhibitor (Z-LETD-FMK). Data are presented as an average of three independent
DMSO. zzzp < 0.0001 compared to MK2206.
(F) Cells were treated with DMSO or MK2206 for 18 hr after knockdown of Fas usi
(PI staining). Experiments were done twice in triplicate. Statistical analysis: ***p <
(G) Immunoblot showing Cyclin D1 expression in GFP-, Skp2-, or mAkt-express
(H) Fas expression in GFP-, Skp2-, or mAkt-expressing cells.
(I) Illustration depicting the mechanism by which Akt inhibition promotes cells deto selectively regress and inhibit tumor progression even in the
absence of Akt activation in this tumor. It was also emerged
from these studies that deregulation of Skp2 expression is a
potential mechanism for resistance to Akt inhibition.
EXPERIMENTAL PROCEDURES
Reagent and Antibodies
RPMI-1640 was purchased from Gibco and HyClone. Fetal bovine serum
(FBS) was purchased fromGemini. MK2206was purchased fromSelleckchem
and ChemieTek. Captisol was purchased from Captisol, a Ligand Company.
Antibodies against phospho-Akt (S473), Akt, phospho-S6, S6, phospho-
FoxO3a, phospho-4EBP1, 4EBP1, cleaved caspase-3, and Gadph from Cell
Signaling Technology. Antibodies to actin from Sigma; Skp2, BIM, Cyclin
D1, and cleaved caspase-8 antibodies are from Cell Signal and Abcam;
FoxO3 antibodies are from Upstate, p27 antibodies are from BD Biosciences,
and Mcl-1 and FAS antibodies are from Santa Cruz Biotechnology. BrdU was
purchased from Dako, and fluorescein mouse second antibody was from
Vector Laboratories.
Mice
C57Bl/6 Akt1f/fmice were generated byOzgene (Australia) as described in Fig-
ure S1. The Rosa26CreERT2 strain (Strain 01XAB) was obtained from Tyler
Jacks’ laboratory (Massachusetts Institute of Technology). The C57Bl/6
p53+/ strain was obtained from the Jackson Laboratory. The double-com-
pound R26CreERT2; p53/ mice and triple-compound R26CreERT2; Akt1f/f;
p53/ mice were generated by mating the three individual strains. NU/NU
nude mice were obtained from Charles River Laboratories.
Genotyping
DNA samples from tail of mice or thymic lymphoma cells were analyzed by
PCR using primer sets that can detect wild-type, deleted p53, Akt1 floxed,
and Rosa26CreERT2 alleles. Primers sequences are as follows: for Akt1 floxed
allele, 50-TCACAGAGATCCACCTGTGC-30 (A1-3loxp), 50-GGGCCTCCATACA
CTCAAGA-30(A1-i4-5R); p53, ACAGCGTGGTGGTACCTTAT, TCCTCGTGCT
TTACGGTATC, TATACTCAGAGCCGGCCT; CreERT2, CCTGATCCTGGCAA
TTTCG (CRE-R1), GGAGCGGGAGAAATGGATATG (CRE-wtR), and AAAGTC
GCTCTGAGTTGTTAT (CRE-uniF).
Isolation of Primary Thymocytes and Establishment of p53-Null
Thymic Lymphoma Cell Lines
Primary thymocytes were isolated by gently pressing the thymus between two
sterile glass slides and then washed with PBS and resuspended in RPMI me-
dium supplemented with 10% fetal bovine serum (FBS) and penicillin-strepto-
mycin. For the generation of thymic lymphoma cell lines, tumors were excised
and minced. Thymic lymphoma cells grew in suspension, and they were main-
tained in RPMI medium supplemented with 10% fetal bovine serum (FBS) and
penicillin-streptomycin.
Isogenic Colorectal Cell Lines
The cell lines HCT116, HCT116-p53/, DLD1, DLD-p53/, SW48, and
SW48-p53/ were previously described (Sur et al., 2009) and were kindly
provided by Dr. Bert Vogelstein. Cells were grown in DMEM mediumexpressing cells following treatment withMK2206 for 18 hr. Data are presented
05 versus GFP; zzp < 0.01, zp < 0.05 versus DMSO in each group.
-expressing cells following treatment with 1 mM MK2206 for 18 hr.
1 mM MK2206 for 18 hr in presence or absence of cell permeable caspase-8
experiments in triplicates ±SEM. ***p < 0.0001 and **p < 0.005 compared to
ng a pool of four siRNAs. Following treatment, cell death was assessed by flow
0.0001 compared to control siRNA. zzzp < 0.0001 compared to DMSO.
ing cells.
ath in p53/ thymic lymphoma.
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supplemented with 10% FBS. For treatment with MK2206, cells (300,000)
were plated on 6-cm plates and 12 hr later were exposed to either MK2206
or DMSO. Apoptosis was quantified with DAPI attaining as previously
described (Kennedy et al., 1997).
qPCR
Total RNA was extracted from cells at the indicated treatment and time point
by using TRIzol reagent (Invitrogen). First-strand cDNA was produced with
SuperScript III reverse transcriptase (Invitrogen). Quantitative real-time PCR
was performed with iQ SYBR green supermix (BIO-RAD) with the iQ5 real-
time PCR detecting system. Relative levels of mRNA were compared by using
actin or cyclophilin A primers to normalize for total RNA input. The reaction
conditions were as follows: 5 min of denaturation at 95C, followed by 45
cycles of denaturation for 15 s at 95C, and annealing and elongation for
1 min at 55C. The mouse primer sequences are as follows: Bim, 50-CGA
CAGTCTCAGGAGGAACC-30 (forward) and 50-CCTTCTCCATACCAGACG
GA-30 (reverse); FasL, 50-TCCGTGAGTTCACCAACCAAA-30 (forward) and
50-GGGGGTTCCCTGTTAAATGGG-30 (reverse); Cycophilin A, 50-TTCACAAA
CCACAATGGCACAGGG-30 (forward) and 50-TGCCGTCCAGCCAATCTGT
CTTAT-30 (reverse); Actin, 50-GGCCGAGGAGCAAGAATGG-30 (forward) and
50-CATGCACTCTGCGATACGCT-30 (reverse).
Western Blot Analysis
Cells were collected and lysed in lysis buffer (1% Triton X-100, 20 mMHEPES,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA) containing phosphatase inhibitors
(5 mM IAA, 20 nM OA, 10 mM sodium pyrophosphate, 20 mM b-glycero-
glycerophosphate,100 mM NaF) and protease inhibitor cocktail (Roche
Applied Science). Solubilized proteins were collected by centrifugation and
quantified using a protein assay reagent (Bio-Rad). Equal amounts of protein
of each sample were resolved by electrophoresis in 8%, 10%, or 12% gel
and transferred to polyvinylidene difluoride membranes (Bio-Rad).
Retroviral Plasmids
The retroviral vector p-MSCV-IRES-GFP was obtained from Addgene (Addg-
ene plasmid 20672). Myristoylated Akt1 (mAkt) was previously described
(Skeen et al., 2006) and was inserted in the Sal1 and Xho1 of p-MSCV-IRES-
GFP. The retroviral vector p-MSCV-Skp2-IRES-GFP was kindly provided by
Michael Deininger and was previously described (Agarwal et al., 2008). The
retroviral vector p-MSCV-p53-IRES-GFPwas kindly provided by Dean Felsher
and was previously described (Giuriato et al., 2006).
Retrovirus Transfection and Infection
Retroviruses were produced in phoenix-ecotropic cells by lipofectamine 2000
transfection. Thymic lymphoma cells were infected by using MagnetoFection.
Before infection, viruses were mixed with ViroMag R/L and incubated at room
temperature for 15 min. Cells were mixed with CombiMag and then plated in
12-well plates and incubated on a magnetic plate for 20 min. After incubation,
ViroMag R/L/viruses mixture were added to the CombiMag/cells mixture and
incubated for 30–60 min following manufacturer’s instructions. Seven days
after infection, GFP-positive cells were sorted using MoFlo Legacy cell sorter
to establish stably expressing cell lines.
Transfection with siRNA
Cells were transfected using MagnetoFection. Two siRNAs pool were
used: non-targeting control siRNA (ON-TARGETplus non-targeting siRNA
SMARTpool, Dharmacon) or a siRNA pool consisting of four siRNAs specific
for mouse Fas (ON-TARGETplus Fas siRNA SMARTpool, Dharmacon). Before
infection, siRNA were mixed with SilentMag and incubated at room
temperature for 15 min. In the meantime, cells were mixed with CombiMag,
plated in a 12-well plate and incubated on the magnetic plate for 20 min. After
incubation, siRNA/SilentMag mixture was added to the CombiMag/cells
mixture on the magnetic plate for 30 min as recommended by manufacturer’s
instructions. Three days post transfection cells were split for experiment and
treated with DMSO or MK2206 for 18 hr. Flow cytometry was then performed
to estimate cell death (PI staining), and samples were collected for
immunoblotting.620 Cell Reports 12, 610–621, July 28, 2015 ª2015 The AuthorsFlow Cytometry, Cell-Cycle Analysis, BrdU Incorporation, and Cell
Sorting
Cells were incubated with bromodeoxyuridine (BrdU) (3 mg/ml) for 2 hr before
the indicated time point for collection. Cells were resuspended in 1 ml PBS
after centrifugation and fixed by adding 3 ml of 100% ethanol dropwise and
stored at 4C. The day before analysis, cells were pelleted by centrifugation
at 2,000 rpm for 5 min. Then cells were solubilized in 2N-HCl with 0.5%
Triton-X followed by neutralization with 0.1 M sodium borate (pH 8.5). Cells
were then incubated with anti-BrdU antibody (Dako) overnight at 4C. The
next day, cells were washed twice by washing buffer (PBS + 0.5% BSA) and
incubated with fluorescein anti-mouse secondary antibody (Vector Labs).
Before analysis, the cells were stainedwith propidium iodide containing RNase
and Triton X-100. Flow cytometry was performed using Beckman Coulter
EPICS Elite ES (Beckman) and analyzed using Cell lab Quanta SC. Cell sorting
was performed using MoFlo Legacy cell sorter.
Assessment of FasL Cell-Surface Expression
Cells were incubated with DMSO or MK-2206 (1mM) for 18 hr before collection
to assess FasL surface expression by FACS. For FasL staining, cell pellets
were resuspended in cell staining buffer (BioLegend) and incubated with
1 mg/3 3 106 cells PE anti-mouse FasL antibody (BioLegend) for 1 hr at 4C
in the dark. The cells were then washed twice in cell staining buffer and coun-
terstained with 7-AAD (500 ng/3 3 106 cells) for another 15 min at 4C in the
dark to assess viability. As a negative control, cells were stained with PE IgG
isotype control antibody. Flow cytometry was then performed using Cell lab
Quanta SC, and both FasL expression (PE positive cells) and apoptosis
(7-AAD positive cells) were quantified.
Caspase-8 Inhibition
Cells were incubated with DMSO orMK-2206 (1 mM) in absence or presence of
20 mM caspase-8 inhibitor (Z-LETD-FMK, Bio-Rad) for 18 hr before collection.
The cells were then washed twice in PBS/5 mM EDTA and stained with 7-AAD
(500 ng/3 3 106 cells) for 15 min at 4C in the dark to assess viability. Flow
cytometry was then performed using Cell lab Quanta SC, and apoptosis
(7-AAD positive cells) was quantified.
Xenograft Assay
Cells were counted and suspended in cold PBS. Cells (1.53 106) were injected
subcutaneously into the rear flank of the nude mice. After palpable tumor for-
mation, mice were randomized into two groups. Either corn oil or tamoxifen
(1 mg/100 ml/per injection) was injected into the nude mice intraperitoneally
every other day for 2 weeks. MK2206 was dissolved in 30% captisol per man-
ufacturer’s instructions and delivered by oral gavage. Tumor sizes were
measured with a caliper and calculated by length 3 height 3 width 3 0.5.
MRI and Tumor Volume Analysis
All animals were sequentially imaged using an Agilent 9.4T preclinical MRI to
screen for tumor growth and treatment response to tamoxifen. T1-weighted
sequences were obtained in axial and coronal planes, using the following pa-
rameters: T1-weighted: repetition time (TR)/echo time (TE) = 900/14ms, matrix
size 192 3 192, 1-mm slice thickness, 20 sequences, six repetitions. Tumor
volume measurements were performed using T1-weighted coronal and axial
image stacks. The tumor volume was calculated by ImageJ measure stacks
to obtain the tumor volume in cubic millimeters. For each time point, all mea-
surements from the available sequences were used to calculate a mean
volume ±SEM in order to limit errors due to manual process.
Statistical Analysis
Statistical analysis was done with unpaired Student’s t tests. Survival curves
were analyzed by log-rank test (Mantel-Cox), and data are expressed as
SEM as indicated in the figure legends. Unless otherwise indicated, all the ex-
periments were performed for at least three times.
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